Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AstraZeneca Deploys High-Sensitivity Troponin Test As Brilinta Biomarker

Executive Summary

In PLATO post hoc analysis, researchers correlate results on new, more sensitive heart damage test from Roche with positive outcomes for Brilinta in preventing events in patients who are managed medically as well as invasively.

Advertisement

Related Content

Is Brilinta The Treatment To Keep AstraZeneca’s Lifeblood Flowing?
Revamping AstraZeneca, Soriot Calls For Focus And Speedier Innovation
AstraZeneca Faces Uphill Battle In Talking U.S. Docs Into Using Brilinta
AstraZeneca Faces Uphill Battle In Talking U.S. Docs Into Using Brilinta
Plavix Takes A Final Bow, But Will It Go Gracefully?
AstraZeneca's Brilinta Approved With Aspirin Warning

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS055097

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel